Grew Fourth Quarter Revenue to $98.2
million
Increased 2023 Total Revenue 22% to $361.1
million
Conference Call and Webcast Today at 4:30 p.m.
ET
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results
for the fourth quarter and full year ended December 31, 2023.
“We closed 2023 with another quarter of excellent results,
driven by our Afirma and Decipher businesses,” said Marc Stapley,
Veracyte’s chief executive officer. “Looking to 2024 and beyond, we
will leverage our Veracyte Diagnostics Platform to continue to
drive near- and long-term revenue. With multiple growth catalysts
over the coming years and with our strong financial discipline, we
expect to achieve positive cash flow for the third consecutive year
and going forward.”
Key Business Highlights
- Grew total test volume to 33,836 in the fourth quarter and
126,977 for the full year 2023, an increase of 21% and 24%,
respectively, compared to the prior year periods.
- Enhanced our Endocrinology offering in 2023 with the launch of
TERT promoter mutation testing for Afirma, the introduction of our
Afirma GRID research tool, and enhancements to our online physician
ordering portal.
- Continued to strengthen the body of evidence for Decipher
Prostate in 2023, adding 8 publications and 16 abstracts to the
clinical-evidence library, reinforcing Decipher’s status as the
only molecular test to receive Level 1 evidence designation in the
National Comprehensive Cancer Network’s (NCCN) prostate cancer
guidelines.
- Acquired C2i Genomics Inc., adding whole-genome minimal
residual disease (MRD) capabilities to our novel Veracyte
Diagnostics Platform and expanding our ability to serve patients
across the cancer care continuum.
- Signed an agreement with Illumina to develop some of our tests
as in vitro diagnostics (IVDs) for use on their NextSeq 550Dx
next-generation sequencing (NGS) instrument, as part of our
multi-platform strategy to accelerate global expansion of our tests
as IVDs.
- Published the clinical validation study for our Percepta Nasal
Swab test in CHEST.
- For the full year, generated $44 million of cash from
operations and ended the year with $216 million of cash and cash
equivalents.
Fourth Quarter 2023 Financial Results
Total revenue for the fourth quarter of 2023 was $98.2 million,
an increase of 22% compared to $80.3 million reported in the fourth
quarter of 2022. Testing revenue was $90.4 million, an increase of
29% compared to $70.3 million in the fourth quarter of 2022, driven
primarily by the strong performance of our Decipher Prostate and
Afirma tests. Product revenue was $3.7 million, an increase of 13%
compared to $3.2 million in the fourth quarter of 2022.
Biopharmaceutical and other revenue was $4.1 million, a decrease of
39% compared to $6.8 million in the fourth quarter of 2022.
Total gross margin for the fourth quarter of 2023, including the
amortization of acquired intangible assets, was 66%, compared to
61% in the fourth quarter of 2022. Non-GAAP gross margin, excluding
the amortization of acquired intangible assets and other
acquisition related expenses was 70%, compared to 67% in the fourth
quarter of 2022.
Operating expenses, excluding cost of revenue, were $100.3
million, which included an impairment charge of $32.0 million
associated with the impairment of HalioDx developed
biopharmaceutical services technology, customer relationships and
customer backlog finite-lived intangible assets, compared to $54.1
million in the fourth quarter of 2022. Non-GAAP operating expenses,
which excludes cost of revenue, amortization of acquired intangible
assets, impairment charges, other acquisition related expenses, and
other restructuring costs, grew 28% to $65.6 million, including a
technology access fee of $3.5 million to develop our IVD kitted
tests on an NGS platform, compared to $51.1 million in the fourth
quarter of 2022.
Net loss for the fourth quarter of 2023 was $28.3 million, and
basic and diluted net loss per common share was $0.39, which
includes the aforementioned $32.0 million impairment charge. Net
cash provided by operating activities in the fourth quarter of 2023
was $15.6 million, an improvement of $5.8 million compared to the
same period in 2022.
A reconciliation of GAAP to non-GAAP financial measures has been
provided in the tables included in this press release. An
explanation of these measures is also included below under the
heading “Note Regarding Use of Non-GAAP Financial Measures.”
Full Year 2023 Financial Results
Total revenue for 2023 was $361.1 million, an increase of 22%
compared to $296.5 million in 2022. Testing revenue was $326.5
million, an increase of 30% compared to $250.5 million in 2022,
driven primarily by the strong performance of our Decipher and
Afirma tests. Product revenue was $15.6 million, an increase of 23%
compared to $12.6 million in 2022. Biopharmaceutical and other
revenue was $18.9 million, a decrease of 43% compared to $33.4
million in 2022, driven by the reduction of customer projects given
overall spending constraints across the industry.
Total gross margin for the full year 2023, including the
amortization of acquired intangible assets, was 64%, compared to
59% in 2022. Non-GAAP gross margin, excluding the amortization of
acquired intangible assets and other acquisition related expenses
was 69%, compared to 66% in 2022.
Operating expenses, excluding cost of revenue, were $315.5
million, an increase of 46% compared to $216.8 million in 2022.
Non-GAAP operating expenses, which excludes cost of revenue,
amortization of acquired intangible assets, impairment charges,
other acquisition related expenses and other restructuring costs,
grew 20% to $240.7 million compared to $200.3 million in 2022.
Net loss for the full year 2023 was $74.4 million and basic and
diluted net loss per common share was $1.02, which includes
impairment charges of $68.3 million in the year. Net cash provided
by operating activities in 2023 was $44.2 million, an increase of
$36.7 million compared to 2022.
A reconciliation of GAAP to non-GAAP financial measures has been
provided in the tables included in this press release. An
explanation of these measures is also included below under the
heading "Note Regarding Use of Non-GAAP Financial Measures."
2024 Financial Outlook
The company is maintaining full-year 2024 total revenue guidance
of $394 million to $402 million and, consistent with prior
guidance, expects cash, cash equivalents and short-term investments
at the end of the year to be $230 million to $234 million.
Conference Call and Webcast Details
Veracyte will host a conference call and webcast today at 4:30
p.m. Eastern Time to discuss the company's financial results and
provide a general business update. The conference call will be
webcast live from the company’s website and will be available via
the following link: https://edge.media-server.com/mmc/p/tkiac6t9.
The webcast should be accessed 10 minutes prior to the conference
call start time. A replay of the webcast will be available for one
year following the conclusion of the live broadcast and will be
accessible on the company’s website at
https://investor.veracyte.com/events-presentations.
The conference call dial-in can be accessed by registering at
the following link:
https://register.vevent.com/register/BI38de228ea0a04e0ab786cfe56be5ca1b
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our Veracyte Diagnostics Platform
delivers high-performing cancer tests that are fueled by broad
genomic and clinical data, deep bioinformatic and AI capabilities,
and a powerful evidence-generation engine, which ultimately drives
durable reimbursement and guideline inclusion for our tests, along
with new insights to support continued innovation and pipeline
development. For more information, please visit www.veracyte.com or
follow us on LinkedIn or X (Twitter).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, and expectations (financial and otherwise), including
with respect to 2024 financial and operating results; statements
regarding the expected benefits of the acquisition of C2i Genomics;
and our intentions with respect to our tests and products, for use
in diagnosing and treating diseases, in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,”
“should,” “may,” “will,” “enable,” “positioned,” “offers,”
“designed” and similar references to future periods. Actual results
may differ materially from those projected or suggested in any
forward-looking statements. These statements involve risks and
uncertainties, which could cause actual results to differ
materially from our predictions, and include, but are not limited
to: our ability to launch, commercialize and receive reimbursement
for our products; our ability to execute on our business strategies
relating to the C2i Genomics acquisition, integration the business
and realize expected benefits and synergies; our ability to
demonstrate the validity and utility of our genomic tests and
biopharma and other offerings; our ability to continue executing on
our business plan; our ability to continue to scale our global
operations and enhance our internal control environment; the impact
of the war in Ukraine and other regional conflicts on European
economies and energy supply, as well as our facilities in France;
the impact of foreign currency fluctuations, increasing interest
rates, inflation, potential government shutdowns and turmoil in the
global banking and finance system; and the performance and utility
of our tests in the clinical environment. Additional factors that
may impact these forward-looking statements can be found under the
caption “Risk Factors” in our Annual Report on Form 10-K filed on
March 1, 2023, and our Quarterly Report on Form 10-Q filed for the
three months ended September 30, 2023, filed on November 8, 2023,
as well as in other documents that we may file from time to time
with the Securities and Exchange Commission. Copies of these
documents, when available, may be found in the Investors section of
our website at investor.veracyte.com. These forward-looking
statements speak only as of the date hereof and, except as required
by law, we specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
Veracyte, the Veracyte logo, Decipher, C2i Genomics, and Afirma
are registered trademarks of Veracyte, Inc., and its subsidiaries
in the U.S. and selected countries.
Note Regarding Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance
with generally accepted accounting principles (GAAP), this press
release and the accompanying tables contain, and reference certain
non‐GAAP results including non-GAAP gross margin, non-GAAP
operating expenses, and non-GAAP loss from operations. These
measures are not meant to be considered superior to or a substitute
for financial measures calculated in accordance with GAAP, and
investors are cautioned that there are material limitations
associated with the use of non-GAAP financial measures as an
analytical tool.
We use non-GAAP measures to internally evaluate and analyze
financial results. We believe these non-GAAP financial measures
provide investors with useful supplemental information about the
financial performance of our business, enable comparison of
financial results between periods where certain items may vary
independent of business performance, and enable comparison of our
financial results with other public companies, many of which
present similar non-GAAP financial measures. However, the non-GAAP
measures we present may be different from those used by other
companies.
We exclude amortization of acquired intangible assets,
acquisition-related expenses relating to our acquisitions of
Decipher Biosciences, HalioDx and C2i Genomics, impairment charges
associated with the nCounter license and other biopharmaceutical
services related HalioDx intangible assets and certain costs
related to restructuring from certain of our non-GAAP measures.
Management has excluded the effects of these items in non-GAAP
measures to help investors gain a better understanding of the core
operating results and future prospects of the company, consistent
with how management measures and forecasts the company's
performance, especially when comparing such results to previous
periods or forecasts. The company encourages investors to carefully
consider its results under GAAP, as well as its supplemental
non‐GAAP information and the reconciliation between these
presentations, to more fully understand its business.
Reconciliations between our GAAP results and non‐GAAP financial
measures are presented in the tables of this release.
VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
(Unaudited)
(In thousands, except share and
per share amounts)
Three Months Ended December
31
Twelve Months Ended December
31
2023
2022
2023
2022
Revenues:
Testing revenue
$
90,385
$
70,269
$
326,542
$
250,544
Product revenue
3,665
3,231
15,588
12,632
Biopharmaceutical and other revenue
4,149
6,797
18,921
33,360
Total revenue
98,199
80,297
361,051
296,536
Operating expenses (1):
Cost of testing revenue
24,105
19,394
88,913
75,317
Cost of product revenue
1,753
2,618
8,666
7,820
Cost of biopharmaceutical and other
revenue
3,518
4,819
15,324
18,445
Research and development
18,673
11,287
57,305
40,603
Selling and marketing
25,260
24,127
101,490
97,560
General and administrative
23,795
18,208
86,229
73,200
Impairment of long-lived assets
32,039
—
68,349
3,318
Intangible asset amortization
4,563
5,264
20,570
21,354
Total operating expenses
133,706
85,717
446,846
337,617
Loss from operations
(35,507
)
(5,420
)
(85,795
)
(41,081
)
Other income, net
5,035
1,979
9,183
4,654
Loss before income taxes
(30,472
)
(3,441
)
(76,612
)
(36,427
)
Income tax (benefit) provision
(2,179
)
403
(2,208
)
133
Net loss
$
(28,293
)
$
(3,844
)
$
(74,404
)
$
(36,560
)
Net loss per common share, basic and
diluted
$
(0.39
)
$
(0.05
)
$
(1.02
)
$
(0.51
)
Shares used to compute net loss per common
share, basic and diluted
73,107,059
71,825,754
72,644,487
71,549,204
1. Cost of revenue, research and
development, sales and marketing and general and administrative
expenses include the following stock-based compensation related
expenses:
Three Months Ended December
31
Twelve Months Ended December
31
2023
2022
2023
2022
Cost of revenue
$
472
$
408
$
1,858
$
1,355
Research and development
1,495
1,332
5,326
6,132
Selling and marketing
2,498
1,297
9,624
6,018
General and administrative
3,142
3,997
16,681
13,951
Total stock-based compensation expense
$
7,607
$
7,034
$
33,489
$
27,456
VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENT
OF COMPREHENSIVE LOSS
(Unaudited)
(In thousands)
Three Months Ended December
31
Twelve Months Ended December
31
2023
2022
2023
2022
Net loss
$
(28,293
)
$
(3,844
)
$
(74,404
)
$
(36,560
)
Other comprehensive income (loss):
Change in currency translation
adjustments
3,765
22,720
7,328
(16,263
)
Net comprehensive loss
$
(24,528
)
$
18,876
$
(67,076
)
$
(52,823
)
VERACYTE, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(In thousands)
December 31,
December 31,
2023
2022
(Unaudited)
(See Note 1)
Assets
Current assets:
Cash and cash equivalents
$
216,454
$
154,247
Short-term investments
—
24,605
Accounts receivable
40,378
44,021
Supplies and inventory
16,128
14,294
Prepaid expenses and other current
assets
12,661
11,469
Total current assets
285,621
248,636
Property, plant and equipment, net
20,584
17,702
Right-of-use assets, operating leases
10,277
13,160
Intangible assets, net
88,593
174,866
Goodwill
702,984
695,891
Restricted cash
876
749
Other assets
5,971
5,418
Total assets
$
1,114,906
$
1,156,422
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
12,943
$
11,911
Accrued liabilities
38,427
37,774
Current portion of deferred revenue
2,008
2,613
Current portion of acquisition-related
contingent consideration
2,657
6,060
Current portion of operating lease
liabilities
5,105
4,070
Current portion of other liabilities
101
186
Total current liabilities
61,241
62,614
Deferred tax liabilities
734
4,531
Acquisition-related contingent
consideration, net of current portion
518
2,498
Operating lease liabilities, net of
current portion
7,525
10,648
Other liabilities
786
931
Total liabilities
70,804
81,222
Total stockholders’ equity
1,044,102
1,075,200
Total liabilities and stockholders’
equity
$
1,114,906
$
1,156,422
1. The condensed consolidated balance
sheet at December 31, 2022 has been derived from the audited
financial statements at that date included in the Company's Form
10-K filed with the Securities and Exchange Commission dated March
1, 2023.
VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
(Unaudited)
(In thousands)
Twelve Months Ended December
31
2023
2022
Operating activities
Net loss
$
(74,404
)
$
(36,560
)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization
27,188
25,928
Loss on disposal of property and
equipment
271
206
Stock-based compensation
33,141
26,734
Deferred income taxes
(3,839
)
133
Interest on end-of-term debt
obligation
—
161
Noncash lease expense
4,158
3,320
Revaluation of acquisition-related
contingent consideration
(5,383
)
154
Impairment loss
68,349
3,318
Effect of foreign currency on
operations
(1,096
)
522
Changes in operating assets and
liabilities:
Accounts receivable
3,887
(4,495
)
Supplies and inventory
(1,694
)
(3,011
)
Prepaid expenses and other current
assets
(458
)
1,390
Other assets
(758
)
(3,049
)
Operating lease liability
(4,330
)
(3,448
)
Accounts payable
(134
)
152
Accrued liabilities and deferred
revenue
(676
)
(3,920
)
Net cash provided by operating
activities
44,222
7,535
Investing activities
Purchase of short-term investments
(19,700
)
(33,519
)
Proceeds from sale of short-term
investments
39,773
—
Proceeds from maturity of short-term
investments
5,000
12,681
Purchases of property, plant and
equipment
(9,961
)
(8,549
)
Net cash provided by (used in) investing
activities
15,112
(29,387
)
Financing activities
Payment of long-term debt
—
(1,281
)
Payment of taxes on vested restricted
stock units
(6,741
)
(3,167
)
Proceeds from the exercise of common stock
options and employee stock purchases
9,578
7,942
Net cash provided by financing
activities
2,837
3,494
Increase (decrease) in cash, cash
equivalents and restricted cash
62,171
(18,358
)
Effect of foreign currency on cash,
cash equivalents and restricted cash
163
(592
)
Net increase (decrease) in cash, cash
equivalents and restricted cash
62,334
(18,950
)
Cash, cash equivalents and restricted
cash at beginning of year
154,996
173,946
Cash, cash equivalents and restricted
cash at end of period
$
217,330
$
154,996
CASH, CASH EQUIVALENTS AND
RESTRICTED CASH
(Unaudited)
(In thousands)
December 31,
December 31,
2023
2022
Cash and cash equivalents
$
216,454
$
154,247
Restricted cash
876
749
Total cash, cash equivalents and
restricted cash
$
217,330
$
154,996
Reconciliation of U.S. GAAP to Non-GAAP
Financial Measures
(Unaudited)
(In thousands)
Identified Expenses
GAAP
Acquisition Related Expenses
(1)
Intangible Assets Amortization
Expense
Other (4)
Total Non-GAAP Measure
Three Months Ended December 31,
2023
Total revenue
$
98,199
$
—
$
—
$
—
$
98,199
Cost of testing revenue
24,105
—
—
—
24,105
Cost of product revenue
1,753
—
—
—
1,753
Cost of biopharmaceutical and other
revenue
3,518
—
—
—
3,518
Intangible asset amortization (2)
4,035
—
4,035
—
—
Gross margin $
64,788
—
4,035
—
68,823
Gross margin %
66
%
70
%
Research and development
18,673
—
—
—
18,673
Selling and marketing
25,260
294
—
—
24,966
General and administrative
23,795
1,867
—
—
21,928
Impairment of long-lived assets
32,039
—
—
32,039
—
Intangible asset amortization
528
—
528
—
—
Total operating expenses excluding cost of
revenue (3)
100,295
2,161
528
32,039
65,567
Income (loss) from operations
$
(35,507
)
$
2,161
$
4,563
$
32,039
$
3,256
Three Months Ended December 31,
2022
Total revenue
$
80,297
$
—
$
—
$
—
$
80,297
Cost of testing revenue
19,394
50
—
—
19,344
Cost of product revenue
2,618
—
—
—
2,618
Cost of biopharmaceutical and other
revenue
4,819
64
—
—
4,755
Intangible asset amortization (2)
4,747
—
4,747
—
—
Gross margin $
48,719
114
4,747
—
53,580
Gross margin %
61
%
67
%
Research and development
11,287
232
—
—
11,055
Selling and marketing
24,127
917
—
—
23,210
General and administrative
18,208
1,368
—
—
16,840
Impairment of long-lived assets
—
—
—
—
—
Intangible asset amortization
517
—
517
—
—
Total operating expenses excluding cost of
revenue (3)
54,139
2,517
517
—
51,105
Income (loss) from operations
$
(5,420
)
$
2,631
$
5,264
$
—
$
2,475
1. Includes transaction related
expenses as well as post-combination compensation expenses. For
each of the three months ended December 31, 2022, and December 31,
2023, adjustments consist primarily of remeasurement of contingent
consideration related to our adoption of a multi-platform IVD
strategy and post-combination compensation expenses associated with
the acquisition of HalioDx. For the three months ended December 31,
2023 adjustments include the transaction related expenses
associated with the acquisition of C2i Genomics.
2. Includes only amortization of
intangible assets identified as developed technology assets through
purchase accounting transactions, which otherwise would have been
allocated to cost of revenue.
3. Includes only amortization of
intangible assets, which otherwise would have been allocated to
research and development, selling and marketing or general and
administrative expense and excludes the cost of revenue ($29.4
million and $26.8 million) and the amortization of intangible
assets which would have been allocated to the cost of revenue ($4.0
million and $4.7 million) for the three months ended December 31,
2023 and for the three months ended December 31, 2022
respectively.
4. For the three months ended
December 31, 2023, includes $32.0 million expense related to the
impairment charge associated with HalioDx developed technology,
customer relationships and customer backlog finite-lived intangible
assets.
Reconciliation of U.S. GAAP to Non-GAAP
Financial Measures
(Unaudited)
(In thousands)
Identified Expenses
GAAP
Acquisition Related Expenses
(1)
Intangible Assets Amortization
Expense
Other (4)
Total Non-GAAP Measure
Twelve Months Ended December 31,
2023
Total revenue
$
361,051
$
—
$
—
$
—
$
361,051
Cost of testing revenue
88,913
83
—
—
88,830
Cost of product revenue
8,666
—
—
—
8,666
Cost of biopharmaceutical and other
revenue
15,324
94
—
—
15,230
Intangible asset amortization (2)
18,464
—
18,464
—
—
Gross margin $
229,684
177
18,464
—
248,325
Gross margin %
64
%
69
%
Research and development
57,305
58
—
—
57,247
Selling and marketing
101,490
2,610
—
—
98,880
General and administrative
86,229
329
—
1,371
84,529
Impairment of long-lived assets
68,349
—
—
68,349
—
Intangible asset amortization
2,106
—
2,106
—
—
Total operating expenses excluding cost of
revenue (3)
315,479
2,997
2,106
69,720
240,656
Income (loss) from operations
$
(85,795
)
$
3,174
$
20,570
$
69,720
$
7,669
Twelve Months Ended December 31,
2022
Total revenue
$
296,536
$
—
$
—
$
—
$
296,536
Cost of testing revenue
75,317
203
—
18
75,096
Cost of product revenue
7,820
—
—
3
7,817
Cost of biopharmaceutical and other
revenue
18,445
325
—
—
18,120
Intangible asset amortization (2)
19,273
—
19,273
—
—
Gross margin $
175,681
528
19,273
21
195,503
Gross margin %
59
%
66
%
Research and development
40,603
1,418
—
—
39,185
Selling and marketing
97,560
3,914
—
493
93,153
General and administrative
73,200
5,245
—
—
67,955
Impairment of long-lived assets
3,318
—
—
3,318
—
Intangible asset amortization
2,081
—
2,081
—
—
Total operating expenses excluding cost of
revenue (3)
216,762
10,577
2,081
3,811
200,293
Loss from operations
$
(41,081
)
$
11,105
$
21,354
$
3,832
$
(4,790
)
1. Includes transaction related
expenses as well as post-combination compensation expenses,
adjustments consist primarily remeasurement of contingent
consideration related to our adoption of a multi-platform IVD
strategy, post-combination compensation expenses associated with
the acquisition of HalioDx and transaction related expenses
associated with the acquisition of C2i Genomics.
2. Includes only amortization of
intangible assets identified as developed technology assets through
purchase accounting transactions, which otherwise would have been
allocated to cost of revenue.
3. Includes only amortization of
intangible assets, which otherwise would have been allocated to
research and development, selling and marketing or general and
administrative expense and excludes the cost of revenue ($112.9 and
$101.6 million) and the amortization of intangible assets which
would have been allocated to the cost of revenue ($18.5 and $19.3
million) for the full year 2023 and 2022 respectively.
4. 2022 includes $3.3 million
expense related to the impairment charge associated with certain
developed technology intangible assets; 2023 includes $34.9 million
expense related to the impairment charge associated with the
nCounter license intangible assets, $32.0 million related to the
impairment charge associated with HalioDx developed technology,
customer relationships and customer backlog finite-lived intangible
assets, $1.4 million related to the departure of the former
executive chair and $1.4 million related to restructuring
costs.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240222312513/en/
Investor Contact: Shayla Gorman investors@veracyte.com
619-393-1545
Media Contact: Tracy Morris media@veracyte.com
650-380-4413
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From May 2023 to May 2024